Skip to Content
Merck
  • High expression of neuro-oncological ventral antigen 1 correlates with poor prognosis in hepatocellular carcinoma.

High expression of neuro-oncological ventral antigen 1 correlates with poor prognosis in hepatocellular carcinoma.

PloS one (2014-03-13)
Yi-An Zhang, Ji-Min Zhu, Jie Yin, Wen-Qing Tang, Yan-Mei Guo, Xi-Zhong Shen, Tao-Tao Liu
ABSTRACT

Neuro-oncological ventral antigen 1 (Nova1) is a neuron-specific RNA-binding protein in human paraneoplastic opsoclonus-myoclonus ataxia accompanying with malignant tumors, but its role in hepatocellular carcinoma (HCC) remains elusive. In this study, we found that overexpressed intratumoral Nova1 was associated with poor survival rate and increased recurrence rate of HCC, especially early recurrence, and was an independent prognostic factor for overall survival rate and tumor recurrence. HCC cell lines over-expressing Nova1 exhibited greater potentials in cell proliferation, invasion and migration, while knockdown of Nova1 had the opposite effects. All these findings indicate that Nova1 may act as a prognostic marker for poor outcome and high recurrence in HCC.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-NOVA1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-NOVA1 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-NOVA1, (C-terminal) antibody produced in mouse, clone 5D9, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-NOVA1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution